History at Codexis

Our History

2022

CDX-6512 Received Orphan Drug Designation For Homocystinuria

seqWell - Partnered in the Genomics and NGS Market

2021

Launched Codex® HiTemp Reverse Transcriptase

Kalsec – Collaboration For Enzyme Supply In Production Of Clean-Label Beverage Ingredient

Improved Enzymes To Further Enhance Tate & Lyle’s Stevia And Allulose Production

2020

Molecular Assemblies – Partnered On Enzymatic DNA Synthesis

Launched Codex® HiFi DNA Polymerase & Codex® HiCap RNA Polymerase

Takeda – Gene Therapy Collaboration And License Agreement

Extended Biotherapeutics Partnering Deal With Nestlé Health Science

2019

Evo T4 DNA Ligase For Next Gen Sequencing Licensed To Roche

Novartis CodeEvolver® Platform License

First Successful Clinical Trial Completed: CDX-6114 For PKU

2018

Commercialized Enzymes For Tate & Lyle Tasteva M® Stevia Sweetener

2017

First Partnering Deal In Biotherapeutics With Nestlé Health Science

2016

First Commercial Enzyme Sold To Food Industry With Tate & Lyle

2015

Merck – CodeEvolver® Platform License

2014

GlaxoSmithKline – CodeEvolver® Platform License

2012

Merck – FDA Approval For Sitagliptin API Process Using CDX-017

2010

Codexis IPO On Nasdaq

2002

Codexis Spun-Out From Maxygen